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Objective. The purpose of this review is to provide a critical appraisal of general and fusion-specifi c clinical practice guidelines on the treatment of chronic nonradicular low back pain and compare the quality and evidence base of fusion guidelines and select payer policies. Summary of Background Data. The treatment of lumbar spondylosis associated with low back pain with lumbar arthrodesis, or fusion, has risen fourfold in the past two decades. Given the signifi cant associated health care costs, there is an increase in clinical guidelines and payer policies infl uencing patient treatment options. Assessment of the medical necessity of a treatment, such as lumbar fusions, based on medical literature will frequently supersede the determination of the physician in the care of their patient. Concerns regarding the effectiveness and costs of the surgical treatment of spinal disorders presenting with low back pain has placed enormous scrutiny on the value of surgical treatments to our patients. As both clinical guidelines and payer policies have a major impact on the perceived effectiveness, or medical necessity, of lumbar fusions for the treatment of chronic nonradicular low back pain, a review of this topic was undertaken.
Methods. An electronic literature search of PubMed, the National Guideline Clearinghouse and the International Network of Agencies for Health Technology Assessment was performed to identify clinical practice guidelines on assessment and treatment of chronic nonradicular low back pain, including those on use of lumbar fusion, as well as relevant technology assessments. A Google search for publicly available private and public payer policies related to fusion was also performed. A hand search was used to identify specifi c studies cited for support of the recommendations made. A modifi ed Appraisal of Guidelines Research and Evaluation instrument was used to provide a standardized assessment method for evaluating the quality of development of the evidence base and recommendations in guidelines and selected health policies. This was combined with appraisal of the evidence base supporting the recommendations. Results. Three systematic reviews of general guidelines from a PubMed search yielding 94 citations were included. A convenience sample of fi ve guidelines with recommendations on fusion was taken from 182 citations identifi ed by the National Guideline Clearinghouse and the International Network of Agencies for Health Technology Assessment searches. Two guidelines were developed by US professional societies, (neurosurgery and pain management), and three were European-based guidelines (Belgium, United Kingdom, and the European Cooperation in Science and Technology). The general guidelines were consistent with their recommendations for diagnosis, but inconsistent regarding recommendations for treatment. All guidelines and payer policies with recommendations on fusion included some set of the primary randomized controlled trials comparing fusion to other treatment options with the exception of one policy. However, no clear pattern with regard to the quality of development was identifi ed based on the modifi ed Appraisal of Guidelines Research and Evaluation tool. There were differences in specialty society recommendations. Conclusion. Three systematic reviews of evidence-based guidelines that provide general guidance for the assessment and treatment of chronic low back pain described consistent recommendations and guidance for the evaluation of chronic low back pain but inconsistent recommendations and guidance for treatment. Five evidence-based guidelines with recommendations on the use of fusion for the treatment of chronic low back pain were evaluated. There is some consistency across guidelines and policies that are government sponsored with regard to development process and critical evaluation of index studies as well as overall recommendations. There were differences in specialty society recommendations. There is heterogeneity in the medical payer policies reviewed possibly due to variations in the literature cited and transparency of the development process. A L umbar spondylosis associated with low back pain is highly prevalent, and the utilization of lumbar arthrodesis, or fusion, has risen fourfold in the past two decades and associated with signifi cant health care costs. 1 , 2 This comes at a time where health care costs in the United States have grown at a pace that threatens the stability of the nation's economy. 3 -5 This has led to the development of payer policies to temper the rise in health care utilization that appear to confl ict with local standard of care and clinical guidelines. 6 Physicians who specialize in spinal care have found themselves challenged to provide their patient with what they believe to be the most appropriate and benefi cial care in an increasingly diffi cult fi nancial environment with decisions increasingly infl uenced by the confl icting interests of doctors, hospitals, and insurers. Such confl icts have raised questions on what constitutes the standard of care for a patient, and what defi nes the best available evidence to support it.
Although there is an increased interest in clinical guidelines and payer policies to be based on a systematic review and interpretation of the available medical literature, medical standard of care is based more on the collaboration between medical professionals involved in the treatment of a given condition. The common legal defi nition of standard of care is how similarly qualifi ed practitioners would have managed the patient's care under the same or similar circumstances. 7 Such a defi nition does not simply defi ne standard of care as what the majority of practitioners would have done, such as would be expected if following a clinical guideline or payer policy, as the courts recognize the respectable minority rule. This allows a practitioner to show that although the course of therapy followed may not be the same as what other practitioners would have followed, it is one that is accepted by a respectable minority of practitioners.
However, with an increased interest in evidence-based medicine, this respectable minority practicing the "art of medicine" has given way to clinical quality initiatives based on peer reviewed literature. The data extracted from literature are frequently the key in assessing the delivery of health care in hospitals and community settings. 8 , 9 Systematic reviews of the literature on the management of specifi ed clinical conditions are often considered the best clinical evidence for a treatment recommendation and such reviews are used to formulate guidelines. 8 , 10 Subsequently, many in health care now advocate that guidelines ensure the provision of safe and appropriate medical care, and assessing compliance with guidelines as a surrogate analysis of a physician's effectiveness in providing treatment. 9 The 1990 Institute of Medicine (IOM) defi nes clinical practice guidelines (CPGs) as "systematically developed statements to assist practitioner and patient decisions about appropriate health care for specifi c clinical circumstances." 11 Further discussion on the National Heart Lung and Blood Institute Web site indicates that guidelines "help clinicians and patients make appropriate decisions about health care" and that they defi ne "practices that meet the needs of most patients in most circumstances." Furthermore, they indicate that clinical guidelines are "useful to managed care organizations and other groups that defi ne benefi t plans for patients or handle health care resources" and that the practices outlined "meet the needs of most patients in most circumstances." 12 One defi nition of health policy says that it is "a fi eld of study and practice in which the priorities and values underlying health resource allocation are determined." 13 Thus, CPGs are developed by a range of groups (clinical specialty groups, government agencies, private organizations, policy makers, and even payers) each with its own perspective, goals, and intended uses. CPGs may also form the basis of clinical care pathways (as discussed in the paper on the Saskatchewan Spine Pathway).
14 They may be used as part of or, in some instances, as the basis of health care and payer policies and therefore infl uence patient care patterns and reimbursement. Thus, it is important to critically examine their development and uses related to and compared with health/ payer policies, which is the focus for this article.
Within a third party payer system, such as in the United States, a patient's access to medical treatment options is frequently determined by a payer's medical policy rather than what the physician believes is standard of care. Such policies are founded on the payer's assessment of the treatment recommendations as "medically necessary." 15 , 16 Medical necessity of a treatment is defi ned as a medical service or procedure that is not for experimental or investigational purposes, and follows generally accepted standards of medical care in the community. However, payers have developed medical policies which supersede the local community standards of medical care with determination of medical necessity based on their interpretation of the medical literature available to them such as in the case of lumbar fusion. 15 , 16 As such, these medical policies act as treatment guidelines to infl uence the physician in providing treatment options in the care of their patient.
description of how recommendations are formulated and disclosure of any potential bias in policy development is important. Threemedical payer policies reviewed are of poor quality with one rated as good with respect to their development based on the modifi ed Appraisal of Guidelines Research and Evaluation tool. Medical payer policies infl uence patient care by defi ning medical necessity for approving treatments, and should be held to the same standards for transparency and development as guidelines. Clinical Recommendations. The spine care community needs to develop (or update) high-quality treatment guidelines. The process should be transparent, methodologically rigorous, and consistent with the Appraisal of Guidelines Research and Evaluation and Institute of Medicine recommendations. This effort should be collaborative across specialty/society groups and would benefi t from patient and public input. Payer policies and treatment guidelines need to be transparent and based on the highest quality evidence available. Clinicians from specialty/society groups, guideline developers and policy makers should collaborate on their development. This process would also benefi t from public and patient input. Key words: clinical guidelines , health care policies , quality , evidence , low back pain , lumbar fusion. Spine 2011 ; 36 : S144 -S163
The concerns regarding the effectiveness and costs of the surgical treatment of spinal disorders presenting with low back pain has placed enormous scrutiny on the value of surgical treatments to our patients. As both clinical guidelines and payer policies have a major impact on the perceived effectiveness, and/or medical necessity of lumbar fusions for the treatment of chronic nonradicular low back pain, a review was undertaken to address three key questions:
1. What evidence-based guidelines provide general guidance for the assessment and treatment of chronic low back pain (CLBP)? 2. What evidence-based guidelines provide specifi c recommendations regarding fusion for the treatment of chronic low back pain? 3. How do the specifi c recommendations on use of fusion in treatment of chronic low back pain from the clinical guidelines compare with those from a selection of payer/reimbursement policies with respect to:
• overall quality based on a modifi ed Appraisal of Guidelines Research and Evaluation (AGREE) critical appraisal tool? • the evidence-base used (which studies, their quality and applicability)? • the fi nal conclusion(s) or recommendations?
MATERIALS AND METHODS

Electronic Literature Search
To address questions one and two, a systematic search was conducted to identify CPGs that pertain to the general assessment and treatment of low back pain (principally by primary care providers) as well as CPGs for use of lumbar fusion for the treatment of chronic nonradicular low back pain published through January 2011. A systematic search was conducted in MEDLINE for such guidelines. Given that clinical guidelines, technology assessments, and policy documents are found primarily in the grey literature, systematic searches of the National Guideline Clearinghouse (NGC) and the International Network of Agencies for Health Technology Assessment Web sites were also done (Grey literature is information that is not controlled by commercial publishing entities and includes academic, industry, and government reports, professional association reports and guidelines, regulatory documents, policies, and other similar literature. It may not be found in usual channels of publication, distribution, and bibliographic control. 19 ). Results were limited to articles published in the English language. Reference lists of key articles were also systematically checked. Detailed information on the search strategy is provided in the supplemental digital material (see Supplemental Digital Content 1, http://links.lww.com/BRS/A535 ).
Two categories of guidelines were considered as alluded to earlier: Guidelines which specifi ed surgical treatment with fusion for pathologies, indications or disease which may cause chronic low back pain ( e.g. , nonradicular back pain with common degenerative changes without deformity or stenosis) and guidelines which described general evaluation and treatment of chronic low back pain that are most applicable to primary care providers were sought. Guidelines related to pharmacological treatment (including steroid injection), use of electrical stimulation, nonsurgical treatment and surgical treatments other than fusion were excluded. In the NGC, guidelines older than 5 years are removed from primary search results and are archived. Those specifi c to use of lumbar fusion for treatment of nonradicular CLBP constitute the primary focus of this report and fall into two broad categories: those developed by professional societies and those developed by government-related or government-sponsored entities. In addition to the inclusion/exclusion criteria described in Table 1 , consideration was given to the potential for broadest impact of guidelines with recommendations regarding fusion. Systematic reviews of clinical guidelines were also considered.
To address the last question, a limited Google search for and selection of health or payer policies related to fusion that encompassed government-related policy as well as private payers was done.
A convenience sample of guidelines and health/payer policies, which were publically available without a fee were considered for inclusion. In keeping with a focus on assessment and treatment of uncomplicated, nonradicular back pain, guidelines, recommendations, and policies related to the following conditions were excluded: Instability, deformity (including spondylolisthesis), spinal stenosis, trauma, tumor, infection, symptomatic neural compression, or previous spinal surgery. Details of inclusion and exclusion criteria are provided in Table 1 .
A hand search of included fusion-specifi c guidelines and policies was conducted to identify specifi c studies cited in support of the recommendations made in these documents. Payer Web sites were searched to identify documentation related to evidence base and policy development processes.
Data Extraction
Each retrieved guideline citation was reviewed by a minimum of two authors. Most were excluded on the basis of information provided by the title or abstract. Citations that appeared to be relevant or that could not be unequivocally excluded from the title and abstract were identifi ed, and the corresponding full-text reports were reviewed by the two reviewers. For all included individual guidelines and payer policies, the following data were abstracted: Guideline or payer source, year, pertinent recommendations or conclusions, citations for studies cited as evidence supporting the recommendation or Decisions Project, which focuses on the use of evidence and transparency in guideline development. 22 The criteria in the modifi ed instrument developed for this article overlap signifi cantly with the recently available IOM standards for clinical guidelines 23 and requirements for guideline inclusion in the NGC. 24 A summary of the domains for the full AGREE tool and overlap with IOM and NGC is found in the supplemental digital content (see Supplemental Digital Content 1, http://links.lww.com/BRS/A535 ) as is information on requirements for guideline inclusion in the NGC. Details of the criteria used to assess the development of guidelines and policies are provided in Table 2 .
The MAGREE tool was applied to guidelines as well as selected health policies as one part of a standardized, objective approach for assessing and comparing clinical guideline and policy development.
It is important to note, that there is not necessarily a oneto-one relationship between the quality of a guideline/policy and the quality of the evidence used to support specifi c recommendations. A guideline may be rigorously developed and well executed and, therefore, of high quality despite the evidence on the clinical question being poor. Likewise, a guideline may be poorly developed and poorly executed (poor quality) despite using highest quality evidence. It is important to consider both the quality of development and the quality of evidence in assessing the overall value of a guideline or policy. It is for these reasons that the MAGREE served as only part of the critical appraisal method.
Two nonclinician authors independently assessed the quality of included guidelines and policies. Discrepancies in ratings were resolved by discussion to arrive at a fi nal rating. If a formal critical appraisal was done on guidelines included in systematic reviews of clinical guidelines, the results of this assessment were reported here, and no independent assessment of them was done for this review.
Level-of-evidence ratings were assigned to individual studies cited as evidence in support of recommendations and policies independently by two reviewers using criteria set by The Journal of Bone and Joint Surgery , American Volume ( J Bone Joint Surg Am ) 18 for treatment studies and modifi ed to delineate criteria associated with methodological quality and described elsewhere 25 (see Supplemental Digital Content 1, http://links.lww.com/BRS/A535 ).
Analysis
Assessments in this review are qualitative and based on evaluation of development quality using objective tools in conjunction with consideration of the evidence cited, as previously described. To reduce the potential for a bias toward surgical treatment in selecting and assessing the quality of guidelines, policies and studies, nonclinician authors with expertise in critical appraisal, and study methodology applied the assessment tools. Qualitative comparison of guidelines and policies by clinicians/surgeon authors (J.S.C., E.M., M.J.L., M.G., and B.A.) included consideration of application of these tools and their domains provided a structured method for formulating conclusions and avoiding bias. information on study design, patient characteristics and demographics, interventions, and inclusion-exclusion criteria were abstracted. All abstracted information formed the basis of a matrix, which provides an overview of the critical appraisal elements used to evaluate and compare guidelines and policies.
Guideline, Policy, and Study Quality
Critical appraisal of guidelines and policies included application of an instrument to evaluate the process of evidence base and recommendation development and in addition to a delineation of studies cited in support of recommendations, their level of evidence and the whether or not the index studies on fusion were included. The primary focus for this evaluation related to effi cacy.
A modifi cation of the AGREE instrument was developed and used to evaluate the quality of included CPGs. The full instrument includes 23 scored items across six domains. It was developed and validated as an international instrument to assess the development process and reporting of CPGs. 20 Additional information on the full instrument can be found at http://www.agreecollaboration.org/pub/ . 21 The supplemental digital content contains additional detail on the full instrument and the modifi cation used in this article (see Supplemental Digital Content 1, http://links.lww.com/BRS/A535 ).
A modifi cation of the AGREE instrument (MAGREE) was developed and used on the basis of the following rationale:
• The primary goal of CPGs and health/payer policies should be to promote the best possible patient outcomes based on diagnostic methods and treatments that work.
• All stakeholders potentially benefi t when clinical recommendations are based on methodologically sound evaluation and synthesis of the best available evidence ( i.e. , that with the least potential for bias available to answer the clinical question), taking into consideration the potential benefi ts, costs and harms of a given course of care.
• Although different organizations may have different purposes, resources, populations served, etc. , for the guidelines they develop, the evidence base, its development and application to recommendations should be largely similar. (A caveat to this is that the publication date of a guideline may not coincide with the availability of the most recent evidence.) • All stakeholders benefi t when there is transparency in guideline development and policy making. Description of how recommendations are formulated and the potential for bias is important for transparency.
With these in mind, a modifi cation of the AGREE instrument, which focuses on the rigor of development of the evidence base and recommendations as the primary set of criteria for critical appraisal of guidelines and policies was felt to be more appropriate than the full, six-domain instrument. The concept for this comes in part from the modifi ed appraisal checklist devised by the Medicaid Evidence-Based 
RESULTS
Study Selection
The structured MEDLINE search yielded 94 citations and the NGC search total of 179 citations. The NGC archives guidelines, which are older than 5 years. As a result, some guidelines retrieved from an earlier search were no longer listed in confi rmatory search results (including the 2005 American Association of Neurological Surgeons/Congress of Neurological Surgeons [AANS/CNS] guidelines) and precise overlap with MEDLINE citations could not be assessed. Three additional unique citations from International Network of Agencies for Health Technology Assessment member sites were found. From the PubMed (MEDLINE) search, three systematic reviews of general clinical guidelines (those intended for primary care providers) were included. As these were considered to provide a reasonably up to date and comprehensive assessment of general guidelines focused on initial assessment and treatment of low back pain for primary care providers, citations for individual guidelines were excluded at the title/ abstract level. From the overall search strategy, 16 potentially relevant guidelines with recommendations on surgical treatment were identifi ed after excluding those related to spinal injections, TENS, and other treatments that were not surgery specifi c. Of the 16 potential guidelines, guidelines were excluded if they focused on diagnosis (n = 1) or conditions or treatment comparisons (n = 9) excluded for this review or were not publically available for free (n = 1). Of the remaining fi ve, the two guidelines developed for or by professional societies in the United States were included. 26 , 27 There were three European-based guidelines identifi ed, one from Belgium, 28 one from the United Kingdom, 29 and one developed by a European Cooperation in Science and Technology (COST) working group B13 30 all of which were included. Although a systematic approach was applied to identify these guidelines, it is likely that there are other guidelines available in the grey literature and the selection is best considered a convenience sample.
For included guidelines and policies, 27 citations supporting their recommendations related to fusion for the treatment of nonradicular chronic low back pain were listed and critically appraised. 2 , 31 -56 This topic focuses on grey literature (clinical guidelines and selected payer policies) and their citations of evidence versus clinical studies systematically searchable via PubMed; thus, the total numbers of citations identifi ed and critically appraised as usually described in a CONSORT diagram would potentially be misleading and are not provided for this article.
What Evidence-Based Guidelines Provide General Guidance for the Assessment and Treatment of Chronic Low Back Pain?
Three systematic reviews of general clinical guidelines, 57 -59 intended for use by primary care providers, for the diagnosis and treatment of chronic low back pain were found ( Table 3 ). The number of guidelines included per review varied from 10 to 15. For management of chronic pain specifi cally, the number of guidelines ranged from 6 to 14, but the acuity of low back pain was not specifi ed in one review (Koes et al ). 59 Recommendations for diagnosis were consistent across guidelines and reviews, with most recommending the following measures:
• assess for "red fl ags" to exclude specifi c pathology or causes of pain; • evaluate severity of pain and functional limitations, triage patients by pain type; • assess for psychosocial factors ("yellow fl ags"); and • imaging is only recommended for patients with red fl ags or suspected specifi c causes of pain.
Recommendations for treatment were noted to be inconsistent across guidelines, but the following were consistently recommended:
• advise against bed rest; • advise patient to stay active, or to engage in nonspecifi c back exercises; • back schools; • multidisciplinary rehabilitation; • analgesics, including non-steroidal anti-infl ammatory drugs (NSAIDs) and weak opioids; and • behavioral therapy.
What Evidence-Based Guidelines Provide Specifi c Recommendations Regarding Fusion for the Treatment of Chronic Low Back Pain?
The only two clinical guidelines from professional societies in the United States that were identifi ed with recommendations 
Evidence inclusion/exclu sion clearly described
Overall quality of evidence considered
Recommendations
Recommendation formula tion method described
Recommendations explic itly linked to evidence
Benefi ts, safety, risks considered for key recom mendations
Member confl icts of inter est identifi ed; role of any external funding source described http://links.lww.com/BRS/A535 ). Ratings related to the quality of development for these clinical guidelines, based on the MAGREE approach, are provided in Table 5 . The APS and National Institute for Health and Clinical Excellence guidelines were rated as good, European COST B13 guideline as moderate, and the AANS/CNS as poor and the Belgian (KCE) rated as fair based on the documentation of the process for development of evidence and recommendations. The fair rating for the KCE resulted from inability to fi nd a description of how the recommendations were formulated by the group developing them. The poor rating for the AANS/CNS was based on lack of documentation of the following processes: recommendation development, inclusion/exclusion criteria and description of safety considerations. In addition to no statement of member confl ict of interest was found. The primary focus of all appeared to be on questions of effi cacy. Safety concerns were most fully described in the COTS B13 and KCE guidelines, with limited mention of them in the APS guideline and none in the specifi c AANS/CNS guideline relevant to this article.
with regard to available documentation on policy development. Documentation regarding development of the evidence base, process for recommendation formulation and specifi c linkage of evidence to recommendations was generally not found in the third-party payer policies or on their Web sites, resulting in a rating of poor. All policies, with the exception of BCBS-NC included citation of the index trials as supporting evidence for coverage decisions, were based on direct citation of the studies and/or use of systematic reviews that used these studies as their basis. ( Table 6 ) All policies considered evidence related to safety except BCBS-NC.
Comparison of Guidelines and Policies
All guidelines and all policies included some set of the primary index RCTs comparing fusion to other treatment options for treatment of patients with CLBP who do not have radiculopathy or stenosis. The AANS/CNS and BCBS-NC did not include all index trials. Although these RCTs were not directly cited in the Aetna and Cigna policies, the systematic reviews (which include technology assessments for the purposes of this article), which were cited in support of their policies, are represented in all of the systematic reviews. Although the guidelines and the Washington State HTA program relied on primary studies and included a meta-analysis of these, the Aetna and Cigna policies appear to have relied more heavily on HTA reports and other systematic reviews and did not provide independent critical appraisal of them or the primary studies. No documentation of a search strategy to identify studies published since the HTA reports or systematic reviews were found.
Based on this small selection of guidelines and policies, there was no clear pattern with regard to the overall fi nal rating for quality of development based on the MAGREE tool. However, the majority of guidelines did provide at least some documentation of a systematic search for evidence, critical appraisal of included studies, and linkage of evidence to recommendations, as did the Washington State HTA. The three private payers did not. In some instances, precise rationale for coverage decisions was not clear and some guidelines provide general statements regarding inconsistency of results across trials or insuffi cient evidence of effi cacy as the rationale for their conclusions.
In general, it appears that there was mostly consistency in recommendations of the APS guideline, European Commission, Washington State HTA, and policies by Cigna and Aetna with regard to exhausting a course of nonsurgical treatment. The government-sponsored guidelines, APS guideline, and the Washington State HTAP for the most part had welldefi ned development processes, were based on critical evaluation and synthesis of available primary/index studies and were reasonably consistent with regard to their overall recommendations for use of fusion in the treatment of nonradicular CLBP. Compared with the AANS/CNS guideline, which was the earliest publication (2005), each of these appear to have had more studies/data available for evaluation and decision making based on information presented in Table 5 .
Overall, the wording and specifi city of recommendations differed. All included guidelines commented that evidence may be limited and/or inconsistent. The two clinical guidelines developed by professional societies in the United States differed with respect to their recommendations. Recommendations ranged from suggesting that fusion in selected patients was recommended by the surgical society 27 to those indicating that fusion is no more effective than intensive rehabilitation and pain management by the pain society. 26 Differences in recommendations may, in part, be due to differences in the development process, included number and types of index studies and their analysis, how up to date the guideline is, development group composition, funding source, variances in specialty perspective, or a combination of such factors. Table 6 provides information on studies cited to support the recommendations. All of the guidelines focused primarily on a set of the same index randomized controlled trials (RCTs) evaluating the effi cacy of fusion versus nonoperative options to the extent that they may have been available at the time of development. The AANS/CNS guideline cites only two of the index trials, perhaps due to its publication date relative to the most recent trial and should be considered out of date. Additional information can be found in the supplemental digital content (see Supplemental Digital Content 1, http://links.lww.com/BRS/A535 ).
How do the specifi c recommendations on use of fusion in treatment of chronic low back pain from the clinical guidelines compare with those from a selection of payer/reimbursement policies with respect to ( a ) Overall development quality, ( b ) the evidence-base used, and ( c ) the fi nal conclusion(s) or recommendations?
Policies Evaluated
Four publically available payer policies were selected to compare with the clinical guidelines included. Their inclusion was intended to represent a range of policies. One is based on the Washington State Health Technology Assessment Program (HTAP) process for making benefi t coverage decisions as one example of how such a process may be used in government policy decisions. 51 The other three policies, Blue Cross Blue Shield of North Carolina (BCBS-NC), 16 Aetna 2010 15 and Cigna 2011, 60 are from private third party payers in the United States. Aetna and Cigna are large payers covering individuals across the United States.
A summary of cover/noncover conditions relevant to the focus of this article from these policies is provided in Table 6 and additional detail provided in the supplemental digital content (see Supplemental Digital Content 1, http://links.lww.com/BRS/A535 ). Given the focus of this article, attention was given to decisions specifi c to fusion for nonradicular CLBP without stenosis or spondylolisthesis.
Overall, it appears that most policies cover these pathologies. Ratings related to the quality of development for these policies, based on the MAGREE tool, are provided in Table 5 . The Washington State HTAP policy process was rated as good whereas the three-private payer policies were rated as poor • There are 3 systematic reviews of evidence-based guidelines that provide general guidance for the assessment and treatment of chronic low back pain.
• The evidence-based guidelines provide consistent recommendations and guidance for the evaluation of chronic low back pain.
• The evidence-based guidelines provide inconsistent recommendations and guidance for the treatment of chronic low back pain.
Q2. What evidence-based guidelines provide specifi c recommendations regarding fusion for the treatment of chronic low back pain?
• There are fi ve evidence-based guidelines providing specifi c recommendations regarding fusion for the treatment of chronic low back pain.
• Some consistency was noted regarding the depth and quality of development process and bottom line recommendations for government sponsored guidelines and the APS guidelines.
• There were differences in specialty society recommendations.
Q3. How do the specifi c recommendations on use of fusion in treatment of chronic low back pain from the clinical guidelines compare with those from a selection of payer/reimbursement policies with respect to:
• overall quality based on MAGREE critical appraisal tool, • the evidence-base used (which studies, their quality and applicability), and • the fi nal conclusion(s) or recommendations.
• There is heterogeneity in the medical payer policies reviewed possibly due to variations in the literature cited and transparency of the development process. A description of how recommendations are formulated and disclosure of any potential bias in policy development is important.
• Three-medical payer policies reviewed are of poor quality with one rated as good with respect to their development based on the MAGREE tool.
• Medical payer policies infl uence patient care by defi ning medical necessity for approving treatments, and should be held to the same standards with regards to transparency and development as guidelines.
The two clinical guidelines developed by professional societies in the United States differed with respect to their recommendations. The AANS/CNS guideline does not include two additional studies included in the APS guideline as these studies were not available when it was developed (2005); therefore, the overall body of evidence included two and four trials, respectively. It should be noted that the AANS/CNS guideline is in the process of being updated.
Although it appears that all guidelines and policies relied upon a similar set of index RCTs, some differences in conclusions or recommendations based on those studies are noted. No clear patterns regarding the differences between clinical guidelines and payer policies in the development quality and recommendations was seen; however, only a small number of policies was included.
DISCUSSION
There is a growing interest in health care costs and quality, with economic value becoming an increasingly important component of health care decision making. Subsequently, an increasing number of CPGs and health care payer policies are being developed to infl uence clinical interventions based on a foundation of evidenced based medicine. The goal is to promote the use of effective treatments, and dissuade the use of less effective ones, and relies on published medical literature and the methods of analyzing the quality of evidence.
Given the known strengths and shortcomings of the currently available medical literature for the treatment of low back pain with surgery, a critical assessment of evidencebased medicine is of paramount importance when determining guidelines for clinical care, which have emerged from various medical societies and organizations. Although some CPGs are made public with voluntary adoption by the physician or medical provider, others are created privately ( e.g. , Milliman Guidelines) and may be the basis of payer policy. It is frequently the policy of health care insurers and payers that determines the rendering of various treatment modalities for a specifi c patient. Stories of physician and patient frustrations abound when the physician's opinion regarding the appropriate management and suggested treatment for a patient differs from what is published in publically available clinical guidelines and payer policies.
Both guidelines and payer policies for medical treatment are presumably based on the tenets of evidence-based medicine, yet there exists heterogeneity across guidelines, policies, and between guidelines and policies for the same specifi ed clinical scenario. In addition to the differences in actual policy, there exists heterogeneity in the quality of guidelines, policies, and the evidence used to support them. Most of the differences found relate to transparency of the development process. We have provided an initial assessment of the quality of currently available guidelines, select policies, and the respective supporting evidence regarding fusion for chronic low back pain. This study is unique in that it focuses attention not only on the quality of evidence, but more importantly current guidelines and policies that are in place.
Given the scope of the subject, one limitation of this review is that it does not strictly follow the usual methods for systematic search, with inclusion and review of all relevant literature and policies pertaining to fusion for the treatment of chronic low back pain. This is in part because of the potentially vast scope of grey literature related to payer policies in particular. In addition, there are many guidelines and policies, which are restricted or not publically accessible, such as the Milliman Guidelines and policies from payers such as WellPoint. We made signifi cant efforts to obtain these nonpublic guidelines and policies, and interactions with individual company representatives proved to be quite challenging, time-consuming, and in the end, unsuccessful. None-the-less, this review provides some insight into how tools and processes for assessing and comparing guidelines and policies might be applied to other focused topics.
Although clinical guidelines are accepted tools in the practice of medicine, payer policies typically have disclaimers noting that they are not treatment guides and should not be used as such. Despite the use of terms such as "benefi ts," "utilization management," or "coverage determination," the payer policies do infl uence the determination of what is medically necessary, and frequently is the fi nal arbiter on the patient's options for medical treatment. In essence, payer policies do function as a clinical guideline in determining the medical necessity of a patient's treatment and whether to authorize it is based on the literature cited in the policy. With this understanding, a goal of this study was to apply an objective approach to evaluating the development of both CPGs and payer policies and the evidence base cited regarding the management of low back pain.
Selection of payer policies for this article was based on relative ease of identifi cation and scope of number of covered individuals in the United States as well as one used for state payer policy and inclusion of a breadth of guidelines (those formulated for or by professional societies with different aims, one developed by an international multidisciplinary team for the European community, and two national European guidelines) provides a limited overview of the broad approaches to development, quality, and reach of these.
A shortcoming of the use of the MAGREE tool developed for this feasibility study is that it has not been validated. The full AGREE instrument is intended for evaluation of clinical guidelines to ensure quality and transparency of the development process. It serves as a standard for assessing such guidelines for inclusion into the NGC 24 and overlaps with tenets put forth by the IOM. 23 The full instrument includes 23 scored items across six domains. Each domain is intended to capture a specifi c dimension of guideline quality. Each item is rated on a 4-point scale by two to four reviewers, and individual domain scores are summed, and a percentage of maximum total score for the domain determined. It was developed and validated as an international instrument to assess the development process and reporting of CPGs. 20 The MAGREE used here focuses on the domains related to rigor of development, clarity of presentation, and editorial independence as these were considered the most universally applicable domains. The domains which were not included (scope and purpose, stakeholder involvement, and applicability) while important to the quality of the development process, were felt to be more specifi c to a given organization and less helpful in comparing across guidelines and policies. Instead of numerical rating, categorical assessment, which emphasizes the fi rst two of these domains, is provided. Thus, some specifi city of guideline development processes are not delineated but rather the result is an overview of general developmental quality. The concept for this approach is based in part on the modifi ed checklist and approach used by the Medicaid Evidence-Based Decisions Project. 22 There is need for continued development of an objective approach for critical appraisal of guidelines and policies. Although the MAGREE may provide insight into the quality of guideline/policy development and was combined with examination of the evidence base the overall appraisal tool needs to include more extensive evaluation/consideration of:
• The rationale provided for recommendations/coverage decisions.
• How the evidence cited does/does not support the recommendation/coverage decision? • Critical appraisal of primary index studies and their fi ndings within the context of study quality, clinically important differences and consideration of estimate stability and consistency.
• The extent to which safety and cost are systematically considered.
• The extent to which public and patient input were sought.
There do not appear to be similar publically available standards for the development of policies by private third party payers as there are for guideline development and use of the MAGREE instrument may or may not be the best assessment tool for evaluating their process. As described previously, it may be benefi cial to providers and patients for both payer policy and guideline developers to follow a transparent process and more explicit linking of recommendations to evidence. There may also be an opportunity for providers and developers of policy to discuss methods for cooperative development of policies and guidelines that is transparent and evidence based. The full AGREE and IOM also suggest that patient views and preferences be sought in the development of guidelines. 23 , 24 This may also be appropriate for development of payer policies.
Three systematic reviews of general guidelines for the assessment and treatment of chronic low back pain provided insight into recommendations, which may be most applicable to primary care providers. The number of guidelines included in each of these 3 reviews varied from 10 to 15 based on the guideline author's interpretation of the literature. The three general guideline reviews had consistent recommendations for diagnosis, noting frequent use of imaging over clinical assessment, and suggested imaging only with red fl ags or specifi c causes of pain are identifi ed. However, the three guideline reviews had inconsistent recommendations for the treatment of low back pain. Heterogeneous treatment effects may be a result of the diverse etiology of low back pain, and contribute to divergent outcomes of a specifi c management option. National patient registries for outcome studies may play a Severe degenerative scoliosis with any of the following:
Isthmic spondylolisthesis, either congenital or acquired pars defect, documented on x-ray, and with persistent back pain, with impairment or loss of function, unresponsive to at least 6 months of conservative nonsurgical care
Recurrent, same level, disc herniation, at least 6 months after previous disc surgery, with recurrent neurogenic symptoms, with impairment or loss of function, unresponsive to at least 3 months of conservative nonsurgical care, and with neural structure compression documented by appropriate imaging, and in a patient who had experienced signifi cant interval relief of prior symptoms Adjacent Segment Degeneration, at least 6 months after previous fusion, with recurrent neurogenic symptoms, with impairment or loss of function, unresponsive to at least 3 months of conservative nonsurgical care, and with neural structure compression documented by appropriate imaging, and in a patient who had experienced signifi cant interval relief of prior symptoms Pseudoarthrosis, documented radiographically, no less than 6 months after initial fusion, with persistent axial back pain, with or without neurogenic symptoms, with impairment or loss of function, in a patient who had experienced signifi cant interval relief of prior symptoms Iatrogenic or degenerative fl at-back syndrome with signifi cant sagittal imbalance; when fusion is performed with spinal osteotomy Lumbar spinal fusion is not covered when it is determined not to be medically necessary:
Lumbar spine fusion surgery is considered not medically necessary unless one of the conditions to the left is met Lumbar spine fusion is considered not medically necessary if the sole indication is any more of the following conditions:
Disk herniation
Degenerative disc disease Initial discectomy/ laminectomy for neural structure decompression Facet syndrome pivotal role in delineating the true effect of symptom management compared with disease treatment. It should be noted that both guidelines and policies may be considered "grey literature" and that variations in this group are not easily discernible. Some grey literature is more rigorously and transparently developed than some peer review literature and policies while some may have subjective bias introduced during the determination of which published studies to include and in their grading of the evidence available, as is true for literature found via sources like PubMed. Differences in literature quality, regardless of source, may play a role in the heterogeneity of the recommendations, despite use of a common set of available medical literature.
Unlike the recommendations for diagnosis, there is less consistency in the recommendations for treatment of chronic low back pain with fusion. The main similarity between the literature ( e.g. , technology assessments) whereas many were published in peer-reviewed journals, searchable in PubMed. As discussed previously, methodological rigor for reports is not necessarily better in peer-reviewed literature or grey literature, so critical appraisal is important. Payers are likely to consider the use of HTA reports, particularly those that are done well ( i.e. , systematic literature search, transparent development) stronger evidence than isolated studies in peer-review literature. The third-party payer policies included here did not appear to have evaluated whether new evidence may be available nor did they provide critical appraisal of the systematic reviews or HTAs. They did not describe the development process used to determine inclusion/exclusion criteria for studies and other evidence. In addition, some payers, such as Washington State HTA (Washington State Health Care Authority is the payor who has the HTA program.), publically share the names of their physician providing expert opinion instrumental in the development of these policies, while others, such as BCBS, typically keep the physicians and their specifi c recommendations confi dential. As both clinical guidelines and payer policies guide a patient's access to treatment, it would be of benefi t to have a level of transparency in both guidelines and policies, which would enhance their credibility and applicability. In this vein, a description of how recommendations are formulated and disclosure of any potential bias in policy development is important for transparency.
On the basis of this review, all the payer policies are rated poor with the exception of the Washington State HTAP policy, which is rated good with respect to the documented processes for evidence and recommendation development. It is not surprising then that there are differences in the primary recommendations from the various payers with respect to lumbar fusions. For example, Cigna restricts the role of lumbar fusion to individuals with at least a year of constant pain with signifi cant functional impairment, which is in contrast to Aetna's primary recommendation that lumbar fusion is experimental and investigational for lumbar spondylosis. Each payer typically provides a list of conditions which they deem to indicate when a lumbar fusion is medically necessary, and tend to agree on its use in deformity, trauma, infection, and cancer, but have differences in their confi rmation needs with imaging and time to determine failure of conservative management. The process by which they performed their literature review to arrive at these primary recommendations is unclear. Aetna notes that they rely on the Milliman Care Guidelines, which are not publicly available for review, and appears to be only representing a large subset of clinical presentations as indications for treatment, and not an encompassing set of recommendations. The Washington State Technology Assessment program seemed to focus on the highest-quality evidence from studies summarized in the report. This report, the Aetna and Cigna policies did discuss aspects of safety in addition to effi cacy.
The need for a systematic and comprehensive review of the literature is only matched by the need for standardization of this review to reach consistent conclusions. Studies need to be graded and the strength of their conclusions be placed treatment guidelines is the inclusion of the best-quality articles comparing fusion and nonoperative treatment 34 , 39 , 41 and better ratings for the development process (MAGREE good or moderate) for all but one guideline. The treatment guidelines (Chou et al 26 and European Commission 30 ) and one policy (the Washington State HTAP) 51 all conclude that there is little evidence to recommend fusion over intensive multidisciplinary nonoperative treatment, but also agree that surgery should be offered to carefully selected patients if appropriate nonoperative treatment has failed or is not available. The AANS/CNS guidelines 27 also recommends fusion for selected patients, but was the one of the lowest-rated treatment guidelines that we reviewed. It should be noted that the AANS/ CNS is in the process of updating their guidelines. Their recommendations and strength of their recommendations may change based on the medical literature published since the initial guideline development in 2005. Overall, the following treatment options were consistently recommended:
• advise against bed rest;
• advise patient to stay active, or to engage in nonspecifi c back exercises; • back schools; • multidisciplinary rehabilitation; • analgesics, including NSAIDs and weak opioids; and • behavioral therapy.
Of interest is that the two clinical guidelines developed by professional societies in the United States differed with respect to their treatment recommendations. This may, in part, be due to differences in perspective between specialty groups. This review is unable to determine whether this really is a relevant concern. A factor that could contribute to differences may be the inclusion of two studies in the APS guideline 26 that were published after the publication of the AANS/CNS guideline 27 and thus consideration of the overall body of evidence across four versus two trials. In addition, there were differences in the documented development processes for these guidelines as refl ected in the MAGREE ratings.
With respect to included payer policies, an overview of the different organizations covering four general types, global health services company (Cigna), American health insurance company (Aetna), one regional payer (BCBS-NC), and State government (Washington State Health Technology Assessment program, Olympia, WA) reveals a high level of heterogeneity not only in primary recommendations but in their development process. It is generally assumed that only the highest quality of evidence is used for development of these policies, which should be substantially the same body of literature for a specifi ed clinical topic. However, it appears that there are discrepancies in the evidence used for policy development, along with a general lack of transparency in their development. The BCBS policy did not incorporate the index studies, unlike the others, which had the index studies represented in one form or another ( i.e. , via inclusion of systematic reviews or HTAs; Table 6 ). Of note is the range of systematic reviews for policy determination, as some are considered grey within clinical context. A rigorous method for the process and development is needed to effectively reduce bias, as it may not be possible to remove all bias. At the very least, transparency and complete disclosure of potential bias is required for credibility and compliance with any recommendations. A patient, physician, hospital, or payer must have complete confi dence in the recommendations generated by any authoritative organization with respect to determining what is considered appropriate and benefi cial medical care. Unfortunately, at this time, there seems to be a void and we feel that there is a pressing need for this in the era of health care reform and value-based medicine. Otherwise, the care of our patients may be dictated more by economics and politics, than by what may be best to help our patients and ensure access to benefi cial medical care. The authors of this article believe that as physicians it is imperative that we play a pivotal role in this.
➢ Key Points
Evidence-based guidelines provide consistent recommendations and guidance for the evaluation of chronic low back pain. There is inconsistency between specialty society guidelines regarding treatment recommendations but some consistency across government-related guidelines. Medical payer policies are inconsistent, but still infl uence patient care by defi ning medical necessity for approving treatments, and should be held to the same standards with regards to transparency and development as guidelines.
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